- Home
- SILC vs GNLX Comparison
SILC vs GNLX Comparison
Compare SILC & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SILC | GNLX |
|---|---|---|
| Founded | 1987 | 2001 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.1M | 133.0M |
| IPO Year | 2002 | 2022 |
Fundamental Metrics
Financial Performance| Metric | SILC | GNLX |
|---|---|---|
| Price | $39.71 | $2.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 127.3K | ★ 168.9K |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | $17.17 | N/A |
| Revenue Next Year | $12.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.34 | $2.29 |
| 52 Week High | $52.58 | $8.54 |
Technical Indicators
Market Signals| Indicator | SILC | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 48.72 | 48.29 |
| Support Level | $38.56 | $2.62 |
| Resistance Level | $50.42 | $3.03 |
| Average True Range (ATR) | 4.45 | 0.17 |
| MACD | -0.82 | -0.02 |
| Stochastic Oscillator | 38.72 | 50.00 |
Price Performance
Historical ComparisonAbout SILC Silicom Ltd
Silicom Ltd is engaged in designing, manufacturing, marketing, and supporting high-performance networking and data infrastructure solutions for a broad range of servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, Switches, Edge AI Solutions, Edge Networking Accessories, 4G 5G Products, FPGA-Based Cards, and Others. Its geographic areas are the USA, North America - other, Israel, Europe, and Asia-Pacific. It derives a majority of its revenue from the USA.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.